Table 5

Enriched X. laevis pathways due to cyclopamine treatment using SEPEA_NT2

KEGG pathway ID

Pathway description

P-value

[path:xla03022]

Basal transcription factors

0.01

[path:xla04010]

MAPK signaling

0.02

[path:xla00460]

Cyanoamino acid metabolism

0.024

[path:xla00550]

Peptidoglycan biosynthesis

0.031

[path:xla02010]

ABC transporters

0.045

[path:xla03050]

Proteasome

0.05

[path:xla00982]

Drug metabolism - cytochrome P450

0.053

[path:xla00830]

Retinol metabolism

0.059

[path:xla04630]

Jak-STAT signaling

0.07

[path:xla04012]

ErbB signaling

0.1

Enriched KEGG [44] pathways (with P-value ≤ 0.1) due to cyclopamine treatment of developing X. laevis, designed to inhibit SHH signaling, using microarray data from GEO [45] [GEO:GSE8293]. P-values were obtained using the SEPEA_NT2 analysis with 1,000 randomizations to compute significance.

Thomas et al. Genome Biology 2009 10:R44   doi:10.1186/gb-2009-10-4-r44